Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 6/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568524 | 0.92 | GRM5 (0.39) | MRGPRX4CXCR2GRM5PARP1MAPT | |
| SCHEMBL4568521 | 0.92 | CXCR2 (0.44) | MRGPRX4CXCR2PARP1MAPTADORA2A | |
| SCHEMBL4568525 | 0.92 | MRGPRX4 (0.44) | MRGPRX4GRM5PARP1MAPTPDE10A | |
| SCHEMBL4568593 | 0.91 | MRGPRX4 (0.41) | MRGPRX4CXCR2MAPTPDE10A | |
| SCHEMBL4568470 | 0.87 | CXCR2 (0.42) | MRGPRX4CXCR2PARP1MAPTADORA2A | |
| SCHEMBL4568527 | 0.87 | MRGPRX4 (0.41) | MRGPRX4GRM5PARP1MAPTADORA2A | |
| SCHEMBL4568518 | 0.86 | CYP19A1 (0.42) | MAPTMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4568520 | 0.86 | MGAM (0.38) | MRGPRX4GRM5PARP1MAPTADORA2A | |
| SCHEMBL3711661 | 0.84 | CXCR2 (0.42) | MRGPRX4CXCR2MAPTPDE10A | |
| SCHEMBL3711836 | 0.84 | MRGPRX4 (0.44) | MRGPRX4PARP1MAPTPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MRGPRX4 273/4885CXCR2 1255/4885GRM5 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.